Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.

NFL (neurofilament light chain) (CSF)

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Neuronal damage
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

A primary structural component of the neuronal cytoskeleton and a marker of large-caliber axonal disintegration elevated. Multiple studies have found that levels of neurofilament light chain  are significantly higher in people with Alzheimer’s disease compared with controls (effect size = 2.313, p <0.0001). On average, levels are about double in AD patients.

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Data collected by multiple groups. Alzforum meta analysis.

  1. “Alzheimer's Disease vs Control: NFL (CSF).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-nfl-csf

  2. “Blood Neurofilament Light a Promising Biomarker for Alzheimer’s?” Alzforum. https://www.alzforum.org/news/research-news/blood-neurofilament-light-promising-biomarker-alzheimers

  3. Lista, S., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., ... & Lamari, F. (2017). Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 108, 355-360. https://www.ncbi.nlm.nih.gov/pubmed/28527630

  4. Hampel, H., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., ... & Lista, S. (2017). Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Ab1–42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimer’s & Dementia, 1(10), 10. https://alzheimer-recherche.org/wp-content/uploads/2016/11/ALZ-DEM_Six-combined-CSF-biomarkers-in-AD_2018_uc-proof1.pdf